EA3132: Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

About this Study

The purpose of this study is to see how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery.

Sponsor Protocol ID:EA3132
IRB Number:2020-0086
Actively Enrolling
Interventional
Phase 2
June 30, 2022
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Pathologically proven diagnosis of squamous cell carcinoma of the head/neck (oral cavity, oropharynx, hypopharynx, or larynx), pathological stage III or IVA
  • Has undergone total resection of primary tumor with curative intent
  • Patients with history of a curatively treated cancer must be disease free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer

Exclusion Criteria
  • Recurrent disease or multiple primaries
  • Pregnant or breast-feeding
  • Previous irradiation to the head and neck what would result in overlap in radiation fields for the current disease

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Eulisa Goins-Freeman
Phone Number: 601-815-3936
Email: efreeman2@umc.edu
Principal Investigator:Robert Hamilton
How to participate in our Clinical Trials